SuperSmart← Back to DiscoverDiscover
What this page shows
Gavi's November 2025 announcement describes advance financing for R21/Matrix-M malaria vaccines and an expected future price of $2.99 per dose. Separately, Novavax's March 2026 filing describes Gavi's security interest in receivables from Serum Institute under the R21 agreement. That agreement pays Novavax for adjuvant supply and through sales-based royalties.
The connection is between vaccine-market financing and contractual security: Gavi supports access to this vaccine while also holding security over a related receivable stream under a separate COVID settlement. These documents do not establish that Gavi receives the royalty payments directly or that any collateral has been seized.
The useful next question is whether increased sales volumes could offset lower per-dose royalty receipts, and what that means for the receivables securing the settlement. Actual contract definitions, supply-price tiers and collections are needed to answer it.
Recorded evidence
Limitations & review notes
- Research draft. Conclusions may change; review the sources and limitations before relying on them.
- Research draft: not independently verified and not actively monitored. The interpretation may change as further documents are reviewed.
- No diversion, improper pricing, default, reduced vaccine access or quantified cash-flow impact is established.
- The November 2025 announcement anticipated the lower price approximately one year later; it does not establish that this price was already effective.
- The procurement contract and actual royalty collections have not been reviewed. More doses need not mean more royalty income if pricing or contractual terms differ.